pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›NELARABINE
drug · small molecule
save

NELARABINE

Marketedupdated 3mo ago
by $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval4 co-mentions · 2 sources
  • companyZydus Lifesciences Ltd2 co-mentions · 2 sources
  • tagRecall2 co-mentions · 2 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.

all catalysts(2)

approval · 2
Apr 4, 2023
approval
$AMRX17.88-1.43%
3y ago
NELARABINE — FDA approval
NELARABINE
→
Nov 6, 2025
approval
$AMRX17.88-1.43%
9mo ago
NELARABINE — FDA approval
NELARABINE
→

Trials studying NELARABINE

  • phase2Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)recruitingn=100
  • phase3Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescentsactive not recruitingn=560
  • phase3Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphomaactive not recruitingn=790
  • phase3The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphomanot yet recruitingn=83

News(0)

no news has mentioned this drug yet

brand
NELARABINE
trade names
Arranon, Atriance
generic
NELARABINE
MOA
12.1 Mechanism of Action Nelarabine is a prodrug of the deoxyguanosine analogue 9-β- D -arabinofuranosylguanine (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by adenosine deaminase (ADA) to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and subsequently converted to the active 5’-triphosphate, ara-GTP. Accumulation of ara-GTP in leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and systemic toxicity of nelarabine.
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 11m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?